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The use of livers from donation after circulatory
death (DCD) is increasing, but concerns exist regard-
ing outcomes following use of grafts from “mar-
ginal” donors. To compare outcomes in transplants
using DCD and donation after brain death (DBD),
propensity score matching was performed for 973
patients with chronic liver disease and/or malig-
nancy who underwent primary whole-liver transplant
between 2004 and 2014 at University Hospitals Birm-
ingham NHS Foundation Trust. Primary end points
were overall graft and patient survival. Secondary
end points included postoperative, biliary and vascu-
lar complications. Over 10 years, 234 transplants
were carried out using DCD grafts. Of the 187
matched DCDs, 82.9% were classified as marginal
per British Transplantation Society guidelines.
Kaplan–Meier analysis of graft and patient survival
found no significant differences for either outcome
between the paired DCD and DBD patients (p = 0.162
and p = 0.519, respectively). Aspartate aminotrans-
ferase was significantly higher in DCD recipients
until 48 h after transplant (p < 0.001). The incidences
of acute kidney injury and ischemic cholangiopathy
were greater in DCD recipients (32.6% vs. 15%
[p < 0.001] and 9.1% vs. 1.1% [p < 0.001], respec-
tively). With appropriate recipient selection, the use
of DCDs, including those deemed marginal, can be
safe and can produce outcomes comparable to those
seen using DBD grafts in similar recipients.
Abbreviations: AKI, acute kidney injury; ALT, alanine
aminotransferase; AST, aspartate aminotransferase;
BAR, balance of risk; BTS, British Transplantation Soci-
ety; CIT, cold ischemic time; CMV, cytomegalovirus;
DBD, donation after brain death; DCD, donation after
circulatory death; DRI, donor risk index; FWIT, func-
tional warm ischemic time; HA-first, hepatic artery-
first; HAT, hepatic artery thrombosis; HCC, hepatocellu-
lar carcinoma; IC, ischemic cholangiopathy; ITU, inten-
sive treatment unit; MELD, Model for End-Stage Liver
Disease; MRCP, magnetic resonance cholangiopancre-
atography; NASH, nonalcoholic steatohepatitis; NMLP,
normothermic machine liver perfusion; PSC, primary
sclerosing cholangitis; PSM, propensity score match-
ing; SD, standard deviation; UHB, University Hospitals
Birmingham NHS Foundation Trust
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Introduction
Liver transplantation is the only curative option for
patients with end-stage liver disease, regardless of etiol-
ogy. Liver disease is the fifth leading cause of death in
the United Kingdom, and the mortality rate continues to
increase (1). In the past decade, the number patients
on the active U.K. liver transplant register has more
than doubled (253 in 2004 to 611 patients in 2015) (2,
3), and in response, there has been a 10-fold increase
in the number of transplants using grafts from donation
after circulatory death (DCD) (13 in 2003 to 177 in
2015) (2,3). In the United Kingdom between April 1,
2014, and March 31, 2015, 15% of patients died or
were removed from the liver transplant waiting list (3);
a proportion of these patients might have been saved if
an appropriate donor had become available.
Donation after brain death (DBD) has been the preferred
practice in countries that use deceased donation since
the Harvard criteria were introduced in 1968 because the
criteria permit oxygenation of the organ until the point of
preservation (4). In the late 1980s, interest in DCDs grew
because of the increasing demand for organs. Following
long-term success with kidney transplants using DCD
grafts (5), specialists turned their attention to the use of
DCD liver grafts, with outcomes benefiting from decades
of improved preservation methods, immunosuppression
and surgical techniques. DCD organs, however, are still
used judiciously, and many factors are taken into account
to minimize the likelihood of an adverse outcome.
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In the United Kingdom, virtually all DCD retrievals are
from controlled donors (Maastricht III) (6), enabling the
retrieval team to closely monitor the functional warm
ischemic time (FWIT)—the point at which oxygen satura-
tion falls below 80% or systolic blood pressure falls
below 50 mmHg until aortic perfusion occurs (7). Organ
ischemia triggers a complex cascade of cellular and
molecular events, including the release of proinflamma-
tory mediators and chemotaxis of cell types that initiate
progressive immunological processes. During the reper-
fusion phase, “the reflow paradox” promotes infiltration
of the tissues by leukocytes, and cellular injury occurs
through a series of pathways that include lipid peroxida-
tion and the creation of reactive oxygen species (8). The
FWIT increases the recipient’s risk of postreperfusion
syndrome (9), primary nonfunction, delayed graft function
(10–12), ischemic cholangiopathy (IC) (13–16), and acute
and chronic kidney disease (17). The cost of DCD trans-
plants can also be 50% higher; IC, for example, is associ-
ated with a higher readmission rate, multiple invasive
procedures and, in some cases, retransplantation
(18–21).
Between April 2013 and March 2014, University Hospi-
tals Birmingham NHS Foundation Trust (UHB) performed
189 liver transplants in 171 patients, and 44 of these
transplants were performed using DCD grafts. The hospi-
tal has a very active DCD program and uses >80% of
the DCD grafts that are offered (22). In 2014, a meta-
analysis by O’Neill et al concluded that DCD transplanta-
tion was associated with an increase in biliary
complications, IC, graft loss and mortality (23). Our aim
was to investigate whether this statement was applica-
ble to our patient population and, as such, to present the
largest single-center study of its kind.
Materials and Methods
UHB approved this study (CARMS-02246). Adult patients (aged >16 years)
who underwent primary orthotopic liver transplantation between July
2004 and July 2014 were initially included. Pediatric transplants and recipi-
ents of grafts from living donors, split livers, machine-perfused grafts,
domino grafts or multiple organs were excluded, as were patients with a
primary etiology of acute liver failure (they would be less likely to receive
a DCD graft). The hospital transplant database is maintained prospectively
and contains information on the donor, the recipient, the retrieval process,
the perioperative period, complications, and follow-up.
During the retrieval process, most teams in the United Kingdom use aor-
tic and portal perfusion to flush the graft effectively (with the only excep-
tion being DBD retrievals in which the pancreas and small bowel are also
being procured). The preferred preservation fluid regimen for procure-
ment without pancreas is 3–4 L of heparinized Marshall’s solution (a low-
viscosity solution) via the aorta under 200 mmHg pressure (which results
in superior organ washout than gravity-alone perfusion) (24,25), 1 L of
UW solution under gravity via the portal vein, and an additional back-table
flush through the artery and portal vein with UW solution. During DCD
procurement, the gallbladder is opened after vascular perfusion, and the
bile duct is divided and then flushed via the gallbladder opening as well
as on the back table. Donor FWIT is generally limited within the United
Kingdom to 30 min for DCD liver procurement. Cold ischemic time (CIT)
is defined as the time between cold aortic perfusion and reperfusion at
implantation via either the portal vein or hepatic artery.
Primary end points were overall graft and patient survival. Secondary end
points included relevant postoperative complication rates within 90 days,
incidence of postoperative acute kidney injury (AKI), ventilator duration,
length of intensive treatment unit (ITU) stay, length of hospital stay, bil-
iary complications (cholangitis, leak, IC, anastomotic stricture) and vascu-
lar complications (hepatic artery stenosis and hepatic artery thrombosis
[HAT]) over the follow-up period. AKI was defined as peak serum crea-
tinine 2.0–2.9 times baseline and thus was included the “risk, injury, fail-
ure, loss and end-stage kidney disease,” or RIFLE, categories. IC was
defined as nonanastomotic biliary strictures in the presence of a patent
hepatic artery confirmed on magnetic resonance cholangiopancreatogra-
phy (MRCP) or endoscopic retrograde cholangiopancreatography by one
of two consultant specialist radiologists. The donor risk index (DRI) and
balance of risk (BAR) score were also calculated for the matched
recipients.
Propensity score matching (PSM) was used to match patients receiving
DCD livers to those receiving DBD livers. PSM is a recognized method of
balancing covariates in two groups to reduce selection bias (26). In our
analysis, we included all donor and recipient variables of clinical relevance
to the posttransplant outcome measures in the propensity score model,
namely, donor age and BMI, days on ventilator, CIT, recipient age and
BMI, recipient primary diagnosis and Model for End-Stage Liver Disease
(MELD) score (Table S1). A total of 187 DCD recipients were successfully
matched to DBD recipients using these criteria, with the remaining 47
DCD recipients excluded from the matched analysis. Year of transplant
was not used as a variable because its inclusion reduced the number of
matched pairs. Additional information regarding the PSM process can be
found in the Supplementary Methods.
Comparisons between organ types in the unmatched data were per-
formed using t-tests for continuous factors and Fisher exact tests for cat-
egorical variables. After matching, normally distributed continuous
variables and nonparametric continuous variables were compared using
the paired t-test and Wilcoxon signed rank test, respectively. The McNe-
mar test was used to compare categorical data. Survival was estimated
using Kaplan–Meier plots with log-rank tests for differences, and adjusted
survival was determined using Cox proportional hazards analyses. Data
were analyzed using SPSS v21 (IBM Corp, Armonk, NY). Continuous vari-
ables were expressed as mean and standard deviation (SD) or median
and interquartile range, as appropriate.
Results
Donor and recipient characteristics
A total of 973 patients underwent primary whole-liver
transplantation for chronic liver disease between July
2004 and July 2014; 234 (24.0%) received DCD organs,
and 739 (76.0%) received DBD organs (Tables 1). All
patients had at least 90 days of follow-up. The mean
donor age was 50.1 years, 52.4% were male and mean
BMI was 26.6. Donor cause of death was consistent with
national data (22). The mean recipient age was 53.1 years,
65.3% were male and mean BMI was 27.5. The most
common causes of chronic disease were alcoholic cirrho-
sis (25.9%), hepatitis C cirrhosis (21.2%), primary biliary
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cirrhosis (12.9%) and primary sclerosing cholangitis (PSC;
10.5%). The mean MELD score was 16, which is in keep-
ing with previous results from our center (17). The number
of transplants using DCD grafts increased from 1 in 2004
to 49 in 2014 (Figure 1). Overall, 83.8% of the 234 DCD
grafts were classified as “marginal,” and 41.0% fulfilled
two or more of the following criteria that define marginal-
ity, according to the British Transplantation Society (BTS)
guidelines (2013): age >50 years, weight >100 kg, inten-
sive care unit stay >5 days, FWIT >20 min, CIT >8 h and
>15% steatosis (27).
Following PSM, 187 pairs of patients were closely
matched, with the majority of variables found to have
Table 1: Demographics of whole data and associated standardized differences
Total DCD DBD Difference
n 973 234 739
Donor factors
Age 50.1 (14.9) 49.1 (16.6) 50.4 (14.3) 0.084
Sex1
Male 510 (52.4%) 132 (56.4%) 378 (51.2%) 0.104
Female 463 (47.6%) 102 (43.6%) 361 (48.8%) 0.104
BMI1 26.6 (4.9) 25.2 (4.0) 27.0 (5.0) 0.398
Virology
CMV +ve 477 (49.0%) 113 (48.3%) 364 (49.3%) 0.020
Hepatitis B +ve 27 (2.8%) 4 (1.7%) 23 (3.1%) 0.092
Hepatitis C +ve 13 (1.3%) 2 (0.9%) 11 (1.5%) 0.055
Days on ventilator1 2.4 (3.5) 2.1 (3.4) 2.5 (3.5) 0.116
Cause of death
Cerebrovascular accident 636 (65.4%) 124 (53.0%) 512 (69.3%) 0.339
Head injury 115 (11.8%) 38 (16.2%) 77 (10.4%) 0.171
Cardiac arrest 67 (6.9%) 28 (12.0%) 39 (5.3%) 0.240
Malignancy 23 (2.4%) 4 (1.7%) 19 (2.6%) 0.062
Other 132 (13.6%) 40 (17.1%) 92 (12.4%) 0.133
Location of donor
Local 129 (13.3%) 33 (14.1%) 96 (13.0%) 0.032
Regional 213 (21.9%) 60 (25.6%) 153 (20.7%) 0.116
National 631 (64.9%) 141 (60.3%) 490 (66.3%) 0.125
Retrieval team
Birmingham 696 (71.5%) 149 (63.7%) 547 (74.0%) 0.224
Other 277 (28.5%) 85 (36.3%) 192 (26.0%) 0.224
DCD FWIT (min) 21 (15–25) 20.6 (6.8) – –
CIT (h)1 8.3 (2.3) 7.1 (1.6) 8.7 (2.4) 0.784
Marginal DCD2 201 (83.8%)
>1 Marginal feature 127 (41.0%)
Recipient factors
Age1 53.1 (10.6) 55.3 (9.3) 52.5 (10.9) 0.276
Sex1
Male 635 (65.3%) 148 (63.2%) 487 (65.9%) 0.056
Female 338 (34.7%) 86 (36.8%) 252 (34.1%) 0.056
BMI1 27.5 (5.1) 26.7 (4.9) 27.7 (5.2) 0.198
MELD1 16 (5.7) 13.8 (4.7) 16.2 (5.8) 0.455
HCC present 266 (27.3%) 88 (37.6%) 178 (24.1%) 0.295
Recipient diagnosis1
Alcohol-related cirrhosis 252 (25.9%) 63 (26.9%) 189 (25.6%) 0.030
Hepatitis C cirrhosis 206 (21.2%) 54 (23.1%) 152 (20.6%) 0.061
Primary biliary cirrhosis 126 (12.9%) 41 (17.5%) 85 (11.5%) 0.171
PSC 102 (10.5%) 22 (9.4%) 80 (10.8%) 0.046
NASH 61 (6.3%) 17 (7.3%) 44 (6.0%) 0.052
Hepatitis B cirrhosis 42 (4.3%) 11 (4.7%) 31 (4.2%) 0.024
Other 184 (18.9%) 26 (11.1%) 158 (21.4%) 0.282
Values expressed as mean (standard deviation) or number (percentage), as appropriate. +ve, positive test result; CIT, cold ischemic
time; CMV, cytomegalovirus; DBD donation after brain death; DCD, donation after circulatory death; FWIT, functional warm ischemic
time; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PSC, primary
sclerosing cholangitis.
1Variables used in propensity score–matching process.
2“Marginal” as described by the British Transplantation Society guidelines (27).
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standardized differences <0.100 (Table 2). In addition,
82.9% of matched DCD grafts were classified as mar-
ginal, as described. There was a trend toward a higher
BAR score in the DCD group (4.88 vs. 4.40, p = 0.053),
and DRI was significantly higher for these recipients
(2.82 vs. 1.80, p < 0.001). This difference was lost when
graft type was removed from the DRI equation (factor of
0.411), resulting in means of 1.87 versus 1.80
Table 2: Demographics of propensity score–matched groups and associated standardized differences
DCD DBD Difference Unmatched DCD
n 187 187 47
Donor factors
Age 49.4 (16.2) 47.7 (14.7) 0.110 48.3 (18.0)
Sex1
Male 102 (54.5%) 106 (56.7%) 0.044 30 (63.8%)
Female 85 (45.5%) 81 (43.3%) 0.044 17 (36.2%)
BMI1 25.5 (4.1) 25.4 (4.7) 0.023 24.1 (3.6)
Virology
CMV +ve 94 (50.3%) 105 (56.1%) 0.116 19 (40.4%)
Hepatitis B +ve 3 (1.6%) 6 (3.2%) 0.105 1 (2.1%)
Hepatitis C +ve 2 (1.1%) 3 (1.6%) 0.043 –
Days on ventilator1 2.2 (3.5) 2.3 (2.5) 0.033 2.1 (3.2%)
Cause of death
Cerebrovascular accident 100 (53.5%) 115 (61.5%) 0.162 24 (51.1%)
Head injury 30 (16.0%) 31 (16.6%) 0.016 8 (17.0%)
Cardiac arrest 22 (11.8%) 7 (3.7%) 0.306 6 (12.8%)
Malignancy 4 (2.1%) 4 (2.1%) 0.000 –
Other 31 (16.6%) 30 (16.0%) 0.016 9 (19.1%)
Location of donor
Local 24 (12.8%) 30 (16.0%) 0.091 9 (19.1%)
Regional 49 (26.2%) 35 (18.8%) 0.178 11 (23.4%)
National 114 (61.0%) 122 (65.2%) 0.087 27 (57.4%)
Retrieval team
Birmingham 115 (61.5%) 160 (85.6%) 0.568 34 (72.3%)
Other 72 (38.5%) 27 (14.4%) 0.568 13 (27.7%)
DCD FWIT (min) 20 (7) 22 (7)
CIT (h)1 7.3 (1.6) 7.4 (2.0) 0.094 6.3 (1.4)
Marginal DCD 155 (82.9%) 41 (87.2%)
>1 Marginal feature 75 (40.1%) 23 (48.9%)
Recipient factors
Age1 54.8 (9.7) 55.2 (10.0) 0.041 57.5 (7.6)
Sex1
Male 119 (63.6%) 188 (59.9%) 0.076 29 (61.7%)
Female 68 (36.4%) 75 (40.1%) 0.076 18 (38.3%)
BMI1 26.9 (4.9) 26.9 (4.8) 0.000 26.1 (4.7)
MELD1 14.0 (4.8) 13.7 (4.4) 0.065 10.7 (5.4)
HCC present 67 (35.8%) 57 (30.5%) 0.113 21 (44.7%)
Recipient diagnosis1
Alcohol-related cirrhosis 47 (25.1%) 43 (23.0%) 0.049 16 (34.0%)
Hepatitis C cirrhosis 48 (25.7%) 42 (22.5%) 0.075 6 (12.8%)
Primary biliary cirrhosis 29 (15.5%) 38 (20.3%) 0.125 12 (25.5%)
PSC 17 (9.1%) 17 (9.1%) 0.000 5 (10.6%)
NASH 12 (6.4%) 10 (5.3%) 0.047 5 (10.6%)
Hepatitis B cirrhosis 9 (4.8%) 9 (4.8%) 0.000 2 (4.3%)
Other 25 (13.4%) 28 (15.0%) 0.046 1 (2.1%)
Risk stratification p-value2
DRI 2.82 (0.64) 1.80 (0.34) <0.001 2.72 (0.61)
DRI minus donor type 1.87 (0.42) 1.80 (0.34) 0.077 1.81 (0.41)
BAR score 4.88 (2.66) 4.40 (2.49) 0.053 3.7 (2.7)
+ve, positive test result; BAR, balance of risk; CIT, cold ischemic time; CMV, cytomegalovirus; DBD donation after brain death; DCD,
donation after circulatory death; DRI, donor risk index; FWIT, functional warm ischemic time; HCC, hepatocellular carcinoma; MELD,
Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PSC, primary sclerosing cholangitis.
1Variables used in propensity score–matching process.
2Paired t-test.
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(p = 0.077). A total of 47 DCD recipients were not
matched to DBD recipients. Their demographics and out-
comes are presented in Tables 2–4 for comparison. The
PSM process does not specify why a match cannot be
performed for a particular case; however, in analysis of
all unmatched DCD recipients, it is likely that a lower
MELD score prohibited a successful match to a DBD
recipient. The demographics of these particular subsets
were very similar otherwise (Table 2).
Postoperative course, outcomes, and complications
There was no significant difference between the paired
DCD and DBD recipients with respect to the postoperative
course (Table 3). Aspartate aminotransferase (AST) was
not normally distributed, thus the values were logged and
reported as geometric means. The resulting values were
significantly higher in DCD recipients until 48 h after
transplant (two-tailed t-test, p < 0.001), returning to a level
similar to that seen in DBD recipients at day 5 (Figure 2).
Kaplan–Meier analysis of overall graft and patient survival
found no significant differences for either outcome
between the paired DCD and DBD recipients (p = 0.162
and p = 0.519, respectively) (Figures 3 and 4). A strati-
fied Cox regression returned a hazard ratio for mortality
of 1.16 (95% confidence interval 0.68–2.01, p = 0.579)
for DCD relative to DBD recipients. Table S2 contains
the etiology of retransplantation (regraft) and death for
matched DCD and DBD recipients as well as unmatched
DCD recipients. For all matched recipients, the most
common causes of death were recurrence of hepatocel-
lular carcinoma (HCC; 23.5%), sepsis (18.0%), pulmonary
complications (13.5%), HAT (11.2%), and cardiac compli-
cations (10.1%). The primary causes of graft loss and
death within the first 30 days were primary nonfunction
(DCD, n = 5 [2.6%] resulting in two deaths; DBD, n = 2
[1.1%]) and HAT for all matched recipients. After 1 year,
recurrence of HCC accounted for most deaths.
The incidence of AKI was significantly greater in DCD
recipients (32.6% vs. 15.0%, p < 0.001), and there was
a trend in the same group toward higher incidence of
postoperative bleeding (12.8% vs. 7.0%, p = 0.080). On
further analysis of renal function, there was no difference
in urea or creatinine between matched recipients at
1 year after transplant (Table 4); however, regardless of
graft type, patients who required short-term filtration
went on to have elevated levels of urea and creatinine at
1 year (filtration vs. no filtration; urea 10.2 [SD 3.3] vs.
8.0 [SD 2.5], p < 0.001; creatinine 124.6 [SD 33.1] vs.



























Figure 1: Number of transplants using DCD donors at
University Hospitals Birmingham NHS Foundation Trust
and proportions of marginal donors. AST, aspartate amino-
transferase; DBD, donation after brain death; DCD, donation
after circulatory death.
Table 3: Postoperative course and outcomes for matched groups and unmatched DCDs
DCD DBD p-value Unmatched DCD
Postoperative course1
Operating time (h) 4.8 (4.0–5.7) 4.9 (4.3–6.0) 0.104 4.9 (4.1–5.9)
Days ventilated 1 (1–2) 1 (1–2) 0.331 1 (1–2)
Days in ITU 3 (2–6) 2 (2–4) 0.066 3 (1–5)
Length of stay (days) 10 (7–15) 10 (7–15) 0.870 7 (9–17)
Estimated graft survival
<30 days 90.4% (0.022) 93.6% (0.018) 95.7% (0.029)
<1 year 82.7% (0.028) 86.1% (0.025) 95.7% (0.029)
Overall graft survival2 0.166
Estimated patient survival
<30 days 94.1% (0.017) 96.3% (0.014) 97.9% (0.021)
<1 year 87.6% (0.025) 88.8% (0.023) 95.6% (0.030)
Overall patient survival2 0.519
Values expressed as median (interquartile range), number (percentage) or percentage (standard error), as appropriate. Graft survival
includes all deaths as well as patients who required retransplantation. DBD donation after brain death; DCD, donation after circulatory
death; ITU, intensive treatment unit.
1Wilcoxon signed rank test.
2Log-rank (Mantel–Cox).
American Journal of Transplantation 2016; 16: 1795–1804 1799
Liver Transplantation Using DCD Grafts
higher incidence of IC in DCD recipients (9.1% vs. 1.1%,
p < 0.001), with similar rates of cholangitis, bile leak,
anastomotic biliary stricture, hepatic artery stenosis, and
HAT (Table 4).
Discussion
This retrospective propensity score–matched study using
data from the largest single-center DCD cohort in the lit-
erature demonstrated similar graft and patient survival
following transplant with DCD and DBD grafts. With the
exception of IC and AKI, we also demonstrated similar
postoperative complication rates.
PSM is an accepted method of estimating the effect of a
treatment by attempting to reduce bias from confounding
variables (26,28). We performed a 1:1 match because this
is the most commonly accepted form of this technique,
which allowed us to determine the impact of receiving a
DCD graft. Despite supposedly resulting in increased pre-
cision, cohort studies matching at ratios of 1:>1 have
been shown to result in somewhat higher levels of bias
(29,30). Any bias introduced by year of transplant, which
was excluded from the PSM process, is expected to be
minimized by the fact that the number of DCD transplants
performed during the early years of the DCD program
were small, and as techniques for the use of DCDs
improved, numbers increased.
Despite the use of DCD grafts remaining controversial,
the transplant community must continue to maximize the
pool of DCD grafts to respond to the increasing inci-
dence of chronic liver disease. The literature presents a
mixed picture, with studies arising from early registry
data showing up to 30% graft failure (10,11) but smaller
high-volume single-center studies demonstrating similar
graft and patient survival (9,31,32). A recent meta-
analysis demonstrated higher incidence of biliary compli-
cations, decreased 1-year graft survival and 3-year patient
survival in DCD recipients; however, the authors com-
mented on significant unexplained differences in effect
size between centers (23), a sentiment echoed by
Callaghan et al in 2013 in their U.K. cohort study (33).
Our data demonstrate similar graft and patient survival in
a matched cohort of “low-risk” recipients, albeit with a
weak trend toward reduced graft survival in the DCD
cohort.
AST levels within the first 5 days following transplant
reflect damage at a hepatocellular level. In 2012, UHB’s
biochemistry department changed its policy on the test-
ing of AST and began using alanine aminotransferase
(ALT) as the standard transaminase in transplant patients.
This meant that 46% of our DCD cohort was excluded
from the AST analysis (compared with 9% of the DBD
cohort). Despite this, we were able to demonstrate a sig-
nificant difference between AST levels within the first
48 h after transplant (Figure 2). Of note, average peak
ALT was also higher in DCD recipients. Leithead et al
were the first to show that peak AST was the only vari-
able associated with the development of AKI (17). They
also demonstrated that ischemia–reperfusion injury was
strongly related to postoperative AKI in DBD recipients
(34). Although AST is also released from damaged renal
tissue, peak AST has been shown to correlate strongly
Table 4: Postoperative complications for matched groups and unmatched DCDs
DCD DBD p-value Unmatched DCD
<90-day postoperative complications1
Cardiac complication 16 (8.6%) 11 (5.9%) 0.405 2 (4.3%)
Postoperative bleeding 24 (12.8%) 13 (7.0%) 0.080 1 (2.1%)
Respiratory complication 20 (10.7%) 29 (15.6%) 0.188 3 (6.4%)
Posttransplant diabetes 11 (5.9%) 18 (9.6%) 0.230 2 (4.3%)
Acute kidney injury 61 (32.6%) 28 (15.0%) <0.001 5 (10.6%)
Renal function 1 year after transplant
Urea (mmol/L) 8.0 (2.6) 8.7 (3.0) 0.847 8.2 (2.2)
Creatinine (mmol/L) 105 (48) 115 (30) 0.763 102 (25)
Biliary complications2
Cholangitis 8 (4.3%) 9 (4.8%) 0.791 –
Bile leak 9 (4.8%) 5 (2.6%) 0.270 1 (2.1%)
Ischemic cholangiopathy 17 (9.1%) 2 (1.1%) <0.001 5 (10.6%)
Anastomotic stricture 27 (14.4%) 23 (12.2%) 0.289 6 (12.8%)
Vascular complications2
Hepatic artery stenosis 5 (2.7%) 2 (1.1%) 0.180 –
Hepatic artery thrombosis 9 (4.8%) 6 (3.2%) 0.416 3 (6.4%)
Combined 14 (7.5%) 8 (4.3%) 0.148 3 (6.4%)
Bold values indicate statistically significant results. DBD donation after brain death; DCD, donation after circulatory death.
1Reported as rates at 90 days, with p-values from the McNemar test.
2Reported as Kaplan–Meier estimated overall rates with p-values from log-rank (Mantel–Cox) tests of all available follow-up.
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with histological grading of hepatic injury (35). Peak AST
was higher in DCD recipients, and in terms of early
complications, AKI was the only complication found to
differ significantly between the two organ types
(p < 0.001). There was a trend toward more postopera-
tive bleeding in DCD recipients, which could be an indica-
tor of inferior graft function and disordered clotting
cascades (p = 0.080). Transplants for HCC or PSC in
recipients with lower MELD scores tend to take less
time than transplants in patients with higher MELD
scores (e.g. those with alcoholic liver disease and recur-
rent spontaneous bacterial peritonitis). In these cases,
the full extent of postreperfusion coagulopathy may
occur following abdominal closure; therefore, we advo-
cate a hemostatic pause before completing the biliary
anastomosis to allow for this in such situations.
When considering late complications, De Olivera et al
demonstrated levels of IC not seen previously in the liter-
ature (2.5% incidence in DCD cohort) and hypothesized
that it was due to a policy of only accepting grafts
exposed to <30 min of warm ischemia and restricting
CIT to 8 h (36). A balance must be reached because
stringent selection criteria will significantly reduce the
number of available organs. Our data show a rate of IC
in DCD recipients of 9.1% compared with 1.1% in DBD
recipients (p < 0.001) and anastomotic biliary stricture
rates of 14.4% and 12.2% for DCD and DBD recipients,
respectively (p = 0.289). These findings are consistent
with a large body of literature (13–15,36,37). Patients
with symptoms or liver function tests indicative of IC
were imaged using MRCP. If confirmed, patients were
managed conservatively (most patients maintained
acceptable biochemistry), and if their symptoms or bio-
chemistry warranted, patients were relisted for transplan-
tation. In this matched cohort, no patients required
relisting, and one patient with IC developed biliary sepsis
and died suddenly as a result.
Our PSM used CIT as a confounding variable, hence the
mean times were similar between the groups (mean of
7.3 h for DCD and 7.4 h for DBD recipients, standardized
difference 0.094). The mean FWIT for DCD grafts was
20 min, which lies just within the marginal range for
FWIT, according to BTS guidelines. When using standard
procurement and preservation techniques, limiting the
FWIT in DCD retrievals is crucial in reducing the
development of IC. Compared with other determinants






























Figure 2: Chart of geometric mean postoperative AST.
There were 187 patients in each matched group (number avail-
able for analysis: DCD, n = 101; DBD, n = 173). *p = 0.030,
****p < 0.001. AST, aspartate aminotransferase; DBD, donation
after brain death; DCD, donation after circulatory death.
Figure 3: Kaplan–Meier curve of patient survival. DBD, dona-
tion after brain death; DCD, donation after circulatory death.
Figure 4: Kaplan–Meier curve of graft survival. DBD, dona-
tion after brain death; DCD, donation after circulatory death.
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on graft function after transplantation. It has been calcu-
lated that 1 min of additional warm ischemia can
increase the risk of IC or hepatic necrosis by up to 16%
(38). Normothermic machine liver perfusion (NMLP) has
shown promise in terms of in situ normothermic regional
perfusion (39), preservation (40), viability testing (41) and
reconditioning of liver grafts. Our center performed the
first transplantation of a discarded liver graft after viability
testing using NMLP (42). In the future, cellular therapy
may also offer some benefit in terms of reducing the
immunological insults triggered by warm ischemia (43,
44).
The DRI introduced by Feng et al focused on donor fac-
tors as well as CIT and retrieval location (which is clo-
sely linked to CIT) and has been reported to be
predictive of graft survival (45). The mean DRI of 2.82
for our DCD recipient cohort would ordinarily predict 1-
year graft survival of 71.4%. In this cohort, 1-year graft
survival was 87.6% (the predicted graft survival rate for
a DRI score of <1). After removing DCD as a determin-
ing factor of graft survival, the mean DRI reduced to
1.87 (vs. 1.80 DBD, which remains unchanged, p =
0.077). The BAR score was devised in 2011 based on
37 255 patients in the United Network for Organ Shar-
ing database (46). Given that neither warm ischemia nor
donor type are taken into account in BAR scoring, the
mean BAR score was 4.88 for DCD recipients and 4.40
for DBD recipients. The survival rates of our matched
cohorts (1-year 87.6% DCD and 88.8% DBD) are in
keeping with published data suggesting that a score of
4–5 predicts 1-year patient survival to be 89–92%. Our
mean BAR score is low because no patients underwent
retransplant or were on preoperative life support, and
our mean MELD score was 16 (5.7). This is <20, the
average MELD of patients in the United States prior to
transplant. Perhaps the MELD score is low across the
cohort because of the exclusion of acute liver failure
and retransplant patients from our analysis. Patients
with HCC also generally had lower MELD scores than
those with end-stage chronic liver disease: 27.3% of
the whole cohort had HCC with a mean MELD score of
14. The mean MELD scores within the matched
groups were even lower (14.0 DCD and 13.7 DBD).
DCD recipients are generally chosen because they
have lower MELD scores than the typical chronic liver
disease patient, and DBD recipients were matched to
them. Because of the size of the DCD cohort, it
was not possible to perform any meaningful matched
analysis on a higher scoring MELD subset. With the
introduction of machine perfusion, it may be possible
in the future to safely transplant marginal donors into
higher risk recipients and compare outcomes in such
a cohort.
There are several reasons why we believe we can
achieve such results. Other than being simply a high-
volume center, we use a number of strategies. At our
hospital, the decision to choose a recipient for a DCD
graft is made between the transplant surgeon and a hep-
atology consultant, and low-risk recipients are chosen for
DCD grafts on the basis that they can better cope with a
reperfusion insult that can occur using marginal grafts.
They are also usually easier to explant, which helps keep
CIT to a minimum. Low risk in terms of etiology usually
means patients with low MELD scores and/or those with
HCC (thus the 37.6% incidence of HCC in DCD recipi-
ents compared with 24.1% in DBD recipients in the
whole cohort) (Table 1). In addition, when transplanting
marginal grafts, our consultant surgeons are acutely
aware of the importance of keeping the second period of
warm ischemia at implantation to a minimum. Recipients
aged >50 years are chosen only if they do not have dia-
betes or cardiovascular disease, and DCD grafts are
rejected if the are moderately steatotic or stiff following
preservation. CIT is kept strictly under 8 h, and we
accept livers that have been exposed to FWIT of up to
40 min (but only if other criteria are within normal range).
To extend into the category of marginal donors, donor
age is the boundary that we invariably push, frequently
accepting DCD grafts from donors aged >50 years.
A number of the consultants have started to use the
technique of hepatic artery-first (HA-first) reperfusion
when utilizing marginal grafts because they believe it
reduces the risk of postreperfusion cardiovascular insta-
bility. A matched study of 40 DCD transplants performed
at our center showed that HA-first reperfusion increased
intraoperative stability and reduced the incidence of
postreperfusion syndrome and peak posttransplant biliru-
bin (47). A much larger study is required to further inves-
tigate the benefits of HA-first reperfusion. In addition to
what has already been discussed in the methods in
terms of procurement, DCD donors are ordinarily with-
drawn on the ITU as long as it is not situated too far
from the operating room, in which case they are with-
drawn in the adjacent anesthetic room. Following asys-
tole, there is a 5-min stand-down period prior to bringing
the patient to the operating room. Overall, 38.5% of
DCD retrievals were performed by teams from other
centers (compared with 14.4% of DBD retrievals)—
another indication of our willingness to accept and trans-
plant marginal donors that have been rejected by other
centers. We are happy to do so because of the under-
standing that all U.K. retrieval teams follow the same rig-
orous procurement guidelines laid out by the BTS. We
do not use thrombolytics or other specific techniques to
target the microcirculation. Vendrell et al demonstrated
that there was no role for the use of exogenous fibrinoly-
sis (48). A study by Simon et al demonstrated no forma-
tion of microthrombi in DCD biopsies at different stages
of cold storage, and they felt that made it less likely that
microthrombi are involved in the pathophysiology of
nonanastomotic strictures after liver transplantation (49).
Time from extubation to arrest (even if oxygen saturation
or blood pressure remain stable) is generally limited to
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60 min, after which a liver would not normally be pro-
cured even if a patient arrested following a subsequently
acceptable FWIT while waiting the remaining 2–3 h for
kidney procurement. This group, however, could be a tar-
get for the viability testing of livers using NMLP (42).
In conclusion, this propensity score–matched single-
center cohort study supports the notion that with appro-
priate recipient selection and other techniques, the use of
DCDs, including those deemed marginal as per national
guidelines, can be used safely and produce outcomes
comparable to those seen using DBD grafts in similar
recipients. Despite accepted risks such as AKI and IC, they
remain a crucial source of donors at a time when the
demand for liver transplantation is increasing.
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